Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 122 clinical trials
HB10101 Multiple Myeloma

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma Patients

  • 0 views
  • 03 Feb, 2021
  • 1 location
Dexamethasone Carfilzomib & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

be able to kill tumor cells without damaging normal cells. Giving dexamethasone, carfilzomib, and nivolumab with pelareorep may work better in treating patients with multiple myeloma.

hysterectomy
tumor cells
oophorectomy
proteasome inhibitor
immunoglobulin
  • 21 views
  • 28 Jan, 2021
  • 2 locations
Study of PF 06863135 in Japanese Participants With Multiple Myeloma

The purpose of this study is to confirm the safety and tolerability of PF-06863135 in Japanese participants with relapsed or refractory MM.

  • 0 views
  • 12 Jun, 2021
  • 4 locations
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on

  • 0 views
  • 15 Apr, 2021
  • 1 location
AGENT-797 in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase I, open-label, dose-escalation, single arm study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in subjects with relapsed/refractory MM, as well as define the RP2D.

  • 0 views
  • 14 May, 2021
  • 1 location
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of fluphenazine in patients with advanced multiple myeloma. The study will also describe the efficacy of this drug.

lenalidomide
progressive disease
refractory multiple myeloma
proteasome inhibitor
measurable disease
  • 11 views
  • 07 Nov, 2020
  • 3 locations
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Master protocol for cell therapy, Phase 1 proof-of-concept studies., in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

  • 0 views
  • 31 May, 2021
  • 1 location
Selinexor Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does

progressive disease
cancer
plasmacytoma
dexamethasone
carfilzomib
  • 5 views
  • 27 Jan, 2021
  • 3 locations
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

  • 0 views
  • 08 Mar, 2021
  • 1 location
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple

  • 4 views
  • 07 Jun, 2021
  • 12 locations